

REMARKS


On January 14, 2008, Examiner Kumar initiated a telephone call with the undersigned, and advised that the claims would be allowable if i) the method claims were amended to delete "or preventing" and ii) the definition of R1 in claims 1 and 14 were limited to the piperazine derivatives in clause (f). When the undersigned called the Examiner on January 22, 2008 to express his agreement to that amendment, the Examiner advised that a final Action was already being processed, and that applicant should make the requested amendment in response to the final Action to be issued, which was issued on January 29, 2008.

By virtue of the present amendment, the claims are now in accordance with the Examiner's January 14, 2008 telephonic request, and additionally contain the limitation (in the method claims) that the recited method is for treating pancreatic or mammary carcinoma (as suggested in numbered paragraph 7 of the final Action). Therefore, applicant seeks reconsideration and withdrawal of the pending rejections.

The Examiner is advised that claims directed to related subject matter are being prosecuted in co-pending application Serial No. 10/521,805, filed January 21, 2005.

It is believed that the present case is in condition for allowance, and a favorable Action is respectfully requested.

Respectfully submitted,



Glenn E. Karta
Attorney for Applicant
Registration No. 30,649
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040